Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$78,214.00+2.48%ETH$2,512.06+3.24%GOLD$4,418.40+0.43%OIL$95.77-1.50%
Smart Investors Daily
FB

NASDAQ · FBIOP

Fortress Biotech, Inc.

Healthcare · Biotechnology

$17.90

Down-$0.21 (-1.16%)

Updated Sep 18, 2026, 11:04 AM

SID Score

6.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
60.62M
P/E ratio
11.44
Dividend yield
0.00%
52-week range
$12.50 – $21.43
Volume
19.13K
Avg. volume
15.83K

Price performance

FBIOP price history

1M range · 0 trading sessions · Daily adjusted prices

FBIOP does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest FBIOP news

The latest Smart Investors Daily articles mentioning FBIOP.

Stock researchCompany · Overview

FBIOP research

Overview

Company profile and research snapshot.

Company profile

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$28.51
Implied upside
—
Analysts
8
FBIOP recent ratings
DateFirmRatingTarget
Feb 23, 2026HC Wainwright & Co.Buy—
Aug 21, 2025HC Wainwright & Co.Buy—
Mar 11, 2025Roth MKMBuy—
Nov 18, 2024HC Wainwright & Co.Buy—
Jul 19, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Journey Medical Corporation to Participate in September 2026 Investor Conferences

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of

Yahoo · Sep 8, 2026

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The prese

Yahoo · Aug 13, 2026

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO® and UNLOXCYT™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biophar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By